Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742767 | 0.82 | FASN (0.41) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL29658271 | 0.82 | FASN (0.41) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL31578094 | 0.76 | FASN (0.37) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL29929146 | 0.74 | FASN (0.43) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL29929098 | 0.74 | FASN (0.43) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL29906159 | 0.74 | FASN (0.43) | FFAR1FASNIMPDH2PTGESALOX5 | |
| SCHEMBL31289413 | 0.73 | LMNA (0.43) | FFAR1FASNPTGESHIF1AEPAS1 | |
| Grandinol SCHEMBL31348060 | 0.73 | FFAR1 (0.47) | FFAR1PTPN1FASNPTGESALOX5 | |
| Jensenone SCHEMBL29361936 | 0.72 | FFAR1 (0.52) | FFAR1PTPN1PTGESALOX5HIF1A | |
| SCHEMBL30426047 | 0.70 | FFAR1 (0.39) | FFAR1PTPN1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12635535-B2 | Multi-level staggered terminal structure and semiconductor package and assembly using the same | BRIDGE SEMICONDUCTOR CORP. (TW) | 2026-05-19 | — | — | US | disclosed |
| EP-4684902-A1 | METHOD FOR CUTTING A WORKPIECE WITH A LASER BEAM | Robust AO GmbH (DE) | 2026-01-28 | — | — | EP | disclosed |
| CN-120060552-A | Detection method for screening red-colored germplasm of Lithospermum candidum in full period | 北京林业大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20240096780-A1 | MULTI-LEVEL STAGGERED TERMINAL STRUCTURE AND SEMICONDUCTOR PACKAGE AND ASSEMBLY USING THE SAME | BRIDGE SMICONDUCTOR CORP. (TW) | 2024-03-21 | — | — | US | disclosed |
| CN-117727729-A | Multi-level staggered terminal structure and semiconductor package and assembly using same | 钰桥半导体股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11873493-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635535-B2 | Multi-level staggered terminal structure and semiconductor package and assembly using the same | GJB2, FLNB, BDNF | FFAR1 3924/4885PTPN1 2082/4885FASN 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.